Advertisement

Topics

Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration

06:53 EDT 20 Jul 2018 | Pharmaceutical Processing

Bristol-Myers Squibb and Gritstone Oncology have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab), and Opdivo plus Yervoy (ipilimumab), in patients with advanced solid tumors.
Contributed Author: 
Bristol-Myers Squibb Company
Topics: 

Original Article: Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...